CIDP Treatment Options

Five treatments are recommended in the 2021 EAN/PNS clinical practice guideline for CIDP — three with Level A (strongest) evidence. Each works differently, is given differently, and suits different patients. Use the pages below to understand each option, then ask the AI for a personalised comparison.

Educational use only. These pages explain how treatments work — they cannot tell you which treatment is right for you. That decision belongs to your neurologist.

Intravenous Immunoglobulin (IVIG)

The most widely used first-line treatment for CIDP, with Level A evidence

Intravenous infusionEvery 3–4 weeks (maintenance)FDA-approved for CIDP

→

Vyvgart Hytrulo (Efgartigimod Alfa + Hyaluronidase)

First FDA-approved FcRn inhibitor for CIDP — a 30-second weekly injection at home

Subcutaneous injectionOnce weeklyFDA-approved June 2024 for adults with CIDP

→

Subcutaneous Immunoglobulin (SCIg)

Weekly home injections that eliminate infusion center visits and the wearing-off effect

Subcutaneous injectionOnce weekly (typical)FDA-approved for CIDP maintenance

→

Plasma Exchange (Plasmapheresis)

A fast-acting procedure that physically removes harmful antibodies from the blood

Intravenous procedure (central venous catheter)5–6 sessions over 10–14 days (per acute course)Not FDA-approved for CIDP specifically; Level A evidence in EAN/PNS 2021 guideline

→

Corticosteroids (Prednisone / IV Methylprednisolone)

Oral or IV steroids that broadly suppress immune activity — effective but with long-term trade-offs

Oral (prednisone) or intravenous (methylprednisolone)Daily oral or monthly IV pulseUsed off-label for CIDP per EAN/PNS 2021 guideline

→

🧠

Not sure which treatment fits your situation?

Ask the AI to compare treatments based on your specific concerns — wearing off, home administration, insurance coverage, pure motor symptoms, and more.

Ask the AI →